1. Home
  2. MPLT vs AMSC Comparison

MPLT vs AMSC Comparison

Compare MPLT & AMSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$7.78

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo American Superconductor Corporation

AMSC

American Superconductor Corporation

SELL

Current Price

$25.74

Market Cap

1.7B

ML Signal

SELL

Company Overview

Basic Information
Metric
MPLT
AMSC
Founded
2018
1987
Country
United States
United States
Employees
N/A
400
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2025
2012

Fundamental Metrics

Financial Performance
Metric
MPLT
AMSC
Price
$7.78
$25.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
4
Target Price
$26.54
★ $61.75
AVG Volume (30 Days)
420.3K
★ 669.8K
Earning Date
12-03-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
82.39
★ 1806.25
EPS
N/A
★ 0.20
Revenue
N/A
★ $900,000.00
Revenue This Year
N/A
$22.95
Revenue Next Year
N/A
$15.15
P/E Ratio
★ N/A
$143.55
Revenue Growth
N/A
N/A
52 Week Low
$7.85
$24.87
52 Week High
$40.43
$68.56

Technical Indicators

Market Signals
Indicator
MPLT
AMSC
Relative Strength Index (RSI) 22.05 31.00
Support Level N/A N/A
Resistance Level $20.46 $31.93
Average True Range (ATR) 0.58 1.40
MACD -0.04 -0.30
Stochastic Oscillator 11.14 4.46

Price Performance

Historical Comparison
MPLT
AMSC

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

About AMSC American Superconductor Corporation

American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.

Share on Social Networks: